Literature DB >> 26669219

Post-Chemotherapy Robotic Retroperitoneal Lymph Node Dissection: Institutional Experience.

Mohamed H Kamel1,2, Nathan Littlejohn1, Michelle Cox3, Ehab A Eltahawy1,2, Rodney Davis1.   

Abstract

PURPOSE: There is little literature on robotic retroperitoneal lymph node dissection (RRPLND) in the difficult post-chemotherapy (PC) setting. We report on the outcome of RRPLND in patients with PC-residual masses.
MATERIALS AND METHODS: Between 2011 and 2015, we performed 12 PC-RRPLND. Mean patient age was 37.8 years. Mean body mass index was 30.78. Nine (75%) patients had nonseminomatus germ cell tumor (NSGCT) and three (25%) patients had seminoma tumors. Cancer stage was III in six (50%), II-C in three (25%), II-B in two (16.7%), and II-A in one (8.03%). International Germ Cell Cancer Collaborative Group (IGCCCG) prognostic classification in the NSGCT was good in six, intermediate in two, and poor in one, and was good in the three seminoma patients.
RESULTS: The procedure was completed effectively in 11 (91.7%) patients. Mean operative time was 312 minutes. The mean estimated blood loss was 475 mL. Mean hospital stay was 3.2 days. Mean number of lymph node excised was 12. Six of the excised masses were ≥5 cm (N3), largest was 7.5 cm. Pathology showed teratoma in five (45.5%), benign/necrosis in five (45.5%), and viable germ cells in one (9%). Major complication (Clavien ≥3) occurred in one patient and minor (Clavien ≤2) in two. Antegrade ejaculation was preserved in eight patients and in one could not be assessed. At a median follow-up of 31 months, no infield or outfield relapses occurred.
CONCLUSIONS: Robotic PC-retroperitoneal lymph node dissection (RPLND) is technically feasible and with acceptable morbidity. It is associated with low blood loss and short hospital stay. More research is needed to assess the long-term outcome and to compare standard open RPLND.

Entities:  

Mesh:

Year:  2016        PMID: 26669219     DOI: 10.1089/end.2015.0673

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  18 in total

Review 1.  Frontiers in robot-assisted retroperitoneal oncological surgery.

Authors:  Wesley W Ludwig; Michael A Gorin; Phillip M Pierorazio; Mohamad E Allaf
Journal:  Nat Rev Urol       Date:  2017-09-12       Impact factor: 14.432

Review 2.  Surgical strategies for postchemotherapy testis cancer.

Authors:  Saum Ghodoussipour; Siamak Daneshmand
Journal:  Transl Androl Urol       Date:  2020-01

3.  Therapeutic supine robotic retroperitoneal lymph node dissection for post-chemotherapy residual masses in testicular cancer: technique and outcome analysis of initial experience.

Authors:  Ashwin Sunil Tamhankar; Saurabh Ramesh Patil; Surya Prakash Ojha; Puneet Ahluwalia; Gagan Gautam
Journal:  J Robot Surg       Date:  2019-01-17

Review 4.  Robot-assisted laparoscopic retroperitoneal lymph node dissection: a minimally invasive surgical approach for testicular cancer.

Authors:  Harsha R Mittakanti; James R Porter
Journal:  Transl Androl Urol       Date:  2020-01

5.  Robot-assisted post-chemotherapy retroperitoneal lymph node dissection in germ cell tumor: is the single-docking with lateral approach relevant?

Authors:  C Overs; J B Beauval; L Mourey; P Rischmann; M Soulié; M Roumiguié; Nicolas Doumerc
Journal:  World J Urol       Date:  2018-01-20       Impact factor: 4.226

6.  Post-chemotherapy robot-assisted retroperitoneal lymph node dissection in non-seminomatous germ cell tumor of testis: Feasibility and outcomes of initial cases.

Authors:  Ekrem İslamoğlu; Çağatay Özsoy; Hakan Anıl; Yasin Aktaş; Mutlu Ateş; Murat Savaş
Journal:  Turk J Urol       Date:  2018-12-20

Review 7.  Robotic RPLND for stage IIA/B nonseminoma: the Princess Margaret Experience.

Authors:  G J Nason; Robert J Hamilton
Journal:  World J Urol       Date:  2022-01-06       Impact factor: 4.226

Review 8.  Outcomes and expanding indications for robotic retroperitoneal lymph node dissection for testicular cancer.

Authors:  Hailiu Yang; Daisy Obiora; Jeffrey J Tomaszewski
Journal:  Transl Androl Urol       Date:  2021-05

9.  Clinical outcome of robot-assisted residual mass resection in metastatic nonseminomatous germ cell tumor.

Authors:  J L H Ruud Bosch; Joost M Blok; Henk G van der Poel; J Martijn Kerst; Axel Bex; Oscar R Brouwer; Simon Horenblas; Richard P Meijer
Journal:  World J Urol       Date:  2020-09-21       Impact factor: 4.226

10.  Re: Singh A et al. Robot-assisted retroperitoneal lymph node dissection: Feasibility and outcome in postchemotherapy residual mass in testicular cancer. Indian J Urol 2017;33:304-9.

Authors:  Mustafa Zafer Temiz; Omer Onur Cakir; Engin Kandirali; Atilla Semercioz
Journal:  Indian J Urol       Date:  2018 Jan-Mar
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.